Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AP601 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on AP601, a putative bispecific antibody targeting NTSE (CD73) and TNFRSF9 (CD137, 4-1BB) (Sep 2025). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AP601 | AP-601|AP 601 | CD73 Antibody 14 TNFRSF9 Antibody 36 | Limited information is currently available on AP601, a putative bispecific antibody targeting NTSE (CD73) and TNFRSF9 (CD137, 4-1BB) (Sep 2025). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07165067 | Phase I | AP601 | A Study of AP601 in Patients With Locally Unresectable Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |